SK13192003A3 - Kryštalická forma omeprazolu - Google Patents

Kryštalická forma omeprazolu Download PDF

Info

Publication number: SK13192003A3
Authority: SK; Slovakia
Prior art keywords: omeprazole; omeprazole form; low; preparation; acetone
Prior art date: 2001-04-25

Application number

SK1319-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Mila� Natasa Hafner

Anton Opar

Barbara Podobnik

Bel�i� Andreja Cizerle

Alenka Ko�ak

Brina Ornik

Uros Urleb

Original Assignee

Lek Pharmaceutical And Chemical Company D.D., Legal Affairs

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-04-25

Filing date

2002-04-24

Publication date

2004-03-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20432882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK13192003(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-04-24 Application filed by Lek Pharmaceutical And Chemical Company D.D., Legal Affairs filed Critical Lek Pharmaceutical And Chemical Company D.D., Legal Affairs

2004-03-02 Publication of SK13192003A3 publication Critical patent/SK13192003A3/sk

Links

SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 title claims abstract description 155
229960000381 omeprazole Drugs 0.000 title claims abstract description 153
238000000034 method Methods 0.000 claims abstract description 34
238000002360 preparation method Methods 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 3
208000018522 Gastrointestinal disease Diseases 0.000 claims abstract 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 40
239000013078 crystal Substances 0.000 claims description 26
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 15
238000010521 absorption reaction Methods 0.000 claims description 14
239000002904 solvent Substances 0.000 claims description 13
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
239000013557 residual solvent Substances 0.000 claims description 10
238000001556 precipitation Methods 0.000 claims description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 5
238000004566 IR spectroscopy Methods 0.000 claims description 4
238000001816 cooling Methods 0.000 claims description 4
239000000725 suspension Substances 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 3
238000000634 powder X-ray diffraction Methods 0.000 claims description 3
229910021529 ammonia Inorganic materials 0.000 claims description 2
238000001914 filtration Methods 0.000 claims description 2
239000011877 solvent mixture Substances 0.000 claims description 2
208000010643 digestive system disease Diseases 0.000 claims 3
238000004090 dissolution Methods 0.000 claims 3
208000018685 gastrointestinal system disease Diseases 0.000 claims 3
230000001376 precipitating effect Effects 0.000 claims 2
239000002253 acid Substances 0.000 claims 1
230000001747 exhibiting effect Effects 0.000 claims 1
239000000126 substance Substances 0.000 abstract description 14
-1 4-methoxy-3,5-dimethyl-2-pyridinyl Chemical group 0.000 abstract description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract description 2
239000000758 substrate Substances 0.000 abstract 1
239000000047 product Substances 0.000 description 14
239000012535 impurity Substances 0.000 description 10
239000008188 pellet Substances 0.000 description 10
239000000243 solution Substances 0.000 description 9
239000000843 powder Substances 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000001157 Fourier transform infrared spectrum Methods 0.000 description 7
238000000354 decomposition reaction Methods 0.000 description 6
238000001953 recrystallisation Methods 0.000 description 6
238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 5
239000002775 capsule Substances 0.000 description 5
238000002441 X-ray diffraction Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000007857 degradation product Substances 0.000 description 4
230000029087 digestion Effects 0.000 description 4
229940088679 drug related substance Drugs 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
239000013543 active substance Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
238000002425 crystallisation Methods 0.000 description 3
230000008025 crystallization Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000013112 stability test Methods 0.000 description 3
238000005406 washing Methods 0.000 description 3
229920002785 Croscarmellose sodium Polymers 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
241000124008 Mammalia Species 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
230000009858 acid secretion Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229960001681 croscarmellose sodium Drugs 0.000 description 2
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
238000000351 diffuse reflectance infrared Fourier transform spectroscopy Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
210000004211 gastric acid Anatomy 0.000 description 2
230000027119 gastric acid secretion Effects 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
229960003943 hypromellose Drugs 0.000 description 2
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000001590 oxidative effect Effects 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
229940126409 proton pump inhibitor Drugs 0.000 description 2
239000000612 proton pump inhibitor Substances 0.000 description 2
238000012430 stability testing Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000003756 stirring Methods 0.000 description 2
125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
UDHXJZHVNHGCEC-UHFFFAOYSA-N Chlorophacinone Chemical group C1=CC(Cl)=CC=C1C(C=1C=CC=CC=1)C(=O)C1C(=O)C2=CC=CC=C2C1=O UDHXJZHVNHGCEC-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
XURCIPRUUASYLR-UHFFFAOYSA-N Omeprazole sulfide Chemical compound N=1C2=CC(OC)=CC=C2NC=1SCC1=NC=C(C)C(OC)=C1C XURCIPRUUASYLR-UHFFFAOYSA-N 0.000 description 1
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
238000003991 Rietveld refinement Methods 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
125000005233 alkylalcohol group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
239000012467 final product Substances 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
201000000052 gastrinoma Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001711 oxyntic cell Anatomy 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000002002 slurry Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
238000005507 spraying Methods 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

SK1319-2003A 2001-04-25 2002-04-24 Kryštalická forma omeprazolu SK13192003A3 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SI200100111A SI20875A (sl)	2001-04-25	2001-04-25	Kristalna oblika omeprazola
PCT/IB2002/001350 WO2002085889A1 (en)	2001-04-25	2002-04-24	Crystalline form of omeprazole

Publications (1)

Publication Number	Publication Date
SK13192003A3 true SK13192003A3 (sk)	2004-03-02

Family

ID=20432882

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1319-2003A SK13192003A3 (sk)	2001-04-25	2002-04-24	Kryštalická forma omeprazolu

Country Status (26)

Country	Link
US (2)	US20040122056A1 (de)
EP (1)	EP1390360B1 (de)
JP (1)	JP4455815B2 (de)
KR (1)	KR20030094358A (de)
CN (1)	CN1531533B (de)
AT (1)	ATE346063T1 (de)
AU (1)	AU2002307892B2 (de)
BG (1)	BG108287A (de)
BR (1)	BR0209103A (de)
CA (1)	CA2445251C (de)
CZ (1)	CZ20032911A3 (de)
DE (1)	DE60216273T2 (de)
HR (1)	HRP20030853B1 (de)
HU (1)	HUP0303928A2 (de)
IL (1)	IL158561A0 (de)
MX (1)	MXPA03009789A (de)
NO (1)	NO20034715L (de)
NZ (1)	NZ528917A (de)
PL (1)	PL366471A1 (de)
RS (1)	RS50880B (de)
RU (1)	RU2286991C2 (de)
SI (2)	SI20875A (de)
SK (1)	SK13192003A3 (de)
UA (1)	UA77671C2 (de)
WO (1)	WO2002085889A1 (de)
ZA (1)	ZA200307988B (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8815916B2 (en)	2004-05-25	2014-08-26	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
ES2246149B1 (es) *	2004-07-02	2007-06-01	Esteve Quimica, S.A.	Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
EP1904064A4 (de) *	2005-07-07	2009-12-02	Reddys Lab Ltd Dr	Omeprazol form b
RU2435782C2 (ru) *	2006-02-22	2011-12-10	Интернешнл Инститьют Оф Кэнсер Иммунолоджи, Инк.	Hla-a*3303-рестриктированный пептид wt1 и содержащая его фармацевтическая композиция
CA2665226C (en)	2006-10-05	2014-05-13	Santarus, Inc.	Novel formulations of proton pump inhibitors and methods of using these formulations
US20080103169A1 (en)	2006-10-27	2008-05-01	The Curators Of The University Of Missouri	Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same
EA200900985A1 (ru)	2007-01-31	2009-12-30	Крка, Товарна Здравил, Д. Д., Ново Место	Способ получения оптически чистого омепразола
RU2339631C1 (ru) *	2007-04-12	2008-11-27	Новосибирский институт органической химии им. Н.Н. Ворожцова СО РАН (НИОХ СО РАН)	Способ получения эзомепразола
WO2010134099A1 (en)	2009-05-21	2010-11-25	Cadila Healthcare Limited	One pot process for preparing omeprazole and related compounds
CN102786513A (zh) *	2011-05-18	2012-11-21	中国医学科学院药物研究所	奥美拉唑晶e型物质及制备方法与在药品和保健品中应用
CN102351846B (zh) *	2011-09-07	2012-08-22	周晓东	一种新的奥美拉唑钠化合物及其药物组合物
KR101459088B1 (ko) *	2012-08-02	2014-12-02	대화제약 주식회사	알-라베프라졸, 이의 금속염의 제조방법
IL312564A (en) *	2021-11-05	2024-07-01	Cinclus Pharma Holding Ab Publ	Polymorphs of the hydrochloride salt of linfarezan glurate
JP2025532389A (ja)	2022-10-04	2025-09-29	ザビリュク，アルセニー	大動脈弁の石灰化の抑制
CN119320381B (zh) *	2024-10-14	2025-12-12	山东益康药业股份有限公司	奥美拉唑与3,5-二硝基苯甲酸的共晶物及其用途
CN119320380B (zh) *	2024-10-14	2025-11-25	山东益康药业股份有限公司	奥美拉唑与2,6-二羟基苯甲酸的共晶物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE7804231L (sv) *	1978-04-14	1979-10-15	Haessle Ab	Magsyrasekretionsmedel
JP3282731B2 (ja) *	1990-06-15	2002-05-20	メルクエンドカムパニーインコーポレーテッド	結晶の構造および大きさを改良する結晶化方法
SE510666C2 (sv) *	1996-12-20	1999-06-14	Astra Ab	Nya Kristallmodifikationer
SI20019A (sl) *	1998-07-13	2000-02-29	LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d.	Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6166213A (en) *	1998-08-11	2000-12-26	Merck & Co., Inc.	Omeprazole process and compositions thereof
UA72748C2 (en) *	1998-11-10	2005-04-15	Astrazeneca Ab	A novel crystalline form of omeprazole
AUPQ841800A0 (en) *	2000-06-28	2000-07-20	Biomolecular Research Institute Limited	Truncated egf receptor
US6627646B2 (en) *	2001-07-17	2003-09-30	Sepracor Inc.	Norastemizole polymorphs

2001
- 2001-04-25 SI SI200100111A patent/SI20875A/sl not_active IP Right Cessation
2002
- 2002-04-24 DE DE60216273T patent/DE60216273T2/de not_active Expired - Lifetime
- 2002-04-24 EP EP02764081A patent/EP1390360B1/de not_active Expired - Lifetime
- 2002-04-24 HU HU0303928A patent/HUP0303928A2/hu unknown
- 2002-04-24 MX MXPA03009789A patent/MXPA03009789A/es active IP Right Grant
- 2002-04-24 PL PL02366471A patent/PL366471A1/xx not_active Application Discontinuation
- 2002-04-24 CA CA2445251A patent/CA2445251C/en not_active Expired - Lifetime
- 2002-04-24 AU AU2002307892A patent/AU2002307892B2/en not_active Expired
- 2002-04-24 US US10/475,239 patent/US20040122056A1/en not_active Abandoned
- 2002-04-24 WO PCT/IB2002/001350 patent/WO2002085889A1/en not_active Ceased
- 2002-04-24 RS YUP-840/03A patent/RS50880B/sr unknown
- 2002-04-24 AT AT02764081T patent/ATE346063T1/de active
- 2002-04-24 HR HR20030853A patent/HRP20030853B1/xx not_active IP Right Cessation
- 2002-04-24 UA UA2003109492A patent/UA77671C2/uk unknown
- 2002-04-24 KR KR10-2003-7013767A patent/KR20030094358A/ko not_active Ceased
- 2002-04-24 CZ CZ20032911A patent/CZ20032911A3/cs unknown
- 2002-04-24 JP JP2002583416A patent/JP4455815B2/ja not_active Expired - Lifetime
- 2002-04-24 IL IL15856102A patent/IL158561A0/xx unknown
- 2002-04-24 SI SI200230491T patent/SI1390360T1/sl unknown
- 2002-04-24 CN CN028089553A patent/CN1531533B/zh not_active Expired - Lifetime
- 2002-04-24 SK SK1319-2003A patent/SK13192003A3/sk unknown
- 2002-04-24 RU RU2003133213/04A patent/RU2286991C2/ru active
- 2002-04-24 BR BR0209103-8A patent/BR0209103A/pt not_active Application Discontinuation
- 2002-04-24 NZ NZ528917A patent/NZ528917A/en unknown
2003
- 2003-10-14 ZA ZA200307988A patent/ZA200307988B/xx unknown
- 2003-10-21 NO NO20034715A patent/NO20034715L/no not_active Application Discontinuation
- 2003-10-24 BG BG108287A patent/BG108287A/bg unknown
2005
- 2005-10-12 US US11/248,461 patent/US7553856B2/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR20030094358A (ko)	2003-12-11
EP1390360B1 (de)	2006-11-22
CN1531533A (zh)	2004-09-22
SI20875A (sl)	2002-10-31
CN1531533B (zh)	2012-07-18
NO20034715L (no)	2003-12-10
ATE346063T1 (de)	2006-12-15
CZ20032911A3 (en)	2004-06-16
HUP0303928A2 (hu)	2004-03-01
CA2445251C (en)	2011-01-04
YU84003A (sh)	2006-08-17
NZ528917A (en)	2006-02-24
RU2286991C2 (ru)	2006-11-10
PL366471A1 (en)	2005-02-07
SI1390360T1 (sl)	2007-04-30
US7553856B2 (en)	2009-06-30
JP2004526786A (ja)	2004-09-02
UA77671C2 (en)	2007-01-15
US20060079560A1 (en)	2006-04-13
NO20034715D0 (no)	2003-10-21
HRP20030853A2 (en)	2005-08-31
EP1390360A1 (de)	2004-02-25
RU2003133213A (ru)	2005-05-10
JP4455815B2 (ja)	2010-04-21
CA2445251A1 (en)	2002-10-31
AU2002307892B2 (en)	2008-04-17
DE60216273D1 (de)	2007-01-04
IL158561A0 (en)	2004-05-12
HRP20030853B1 (en)	2011-11-30
RS50880B (sr)	2010-08-31
BG108287A (bg)	2005-04-30
MXPA03009789A (es)	2005-03-07
DE60216273T2 (de)	2007-05-31
ZA200307988B (en)	2004-10-14
US20040122056A1 (en)	2004-06-24
BR0209103A (pt)	2004-07-13
WO2002085889A1 (en)	2002-10-31

Publication	Publication Date	Title
JP3377218B2 (ja)	2003-02-17	オメプラゾールナトリウム塩
DE60203260T2 (de)	2006-02-02	Pharmazeutische kombination, die ein 4-chinazolinamin und paclitaxel, carboplatin oder vinorelbin enthält, zur behandlung von krebs
CA2445251C (en)	2011-01-04	Crystalline form of omeprazole
EP1273581B1 (de)	2005-03-23	Neuer Prozess zur Herstellung von S-Omeprazol-Magnesiumsalz-Trihydrat
RU2237666C2 (ru)	2004-10-10	Калиевая соль (s)-омепразола, способ ее получения и фармацевтический препарат на ее основе
US20100286400A1 (en)	2010-11-11	Crystalline solvated forms of (r)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1h-benzimidazole
SK5452001A3 (en)	2001-11-06	New crystalline form of omeprazole
AU2002307892A1 (en)	2003-04-17	Crystalline form of omeprazole
AU2015318324A1 (en)	2017-04-06	Crystalline forms of tyrosine kinase inhibitors and their salts
DE60023154T2 (de)	2006-06-22	Alkoxy-substituierte benzimidazolverbindungen , diese enthaltende arzneimittel und ihre verwendung
HK40082657A (en)	2023-06-16	Pharmaceutical composition, formulation thereof, preparation method therefor and use thereof
MXPA99011674A (en)	2000-05-01	Omeprazole sodium salt
HK1051681B (en)	2005-08-19	New process for the preparation of the trihydrate of the magnesium salt of s-omeprazole